000			05243cam a2200649Ii 4500
001			ocn940961473
003			OCoLC
005			20190719103214.0
006			m o d
007			cr cnu|||unuuu
008			160225s2016 enk o 001 0 eng d
040			_aN$T _beng _erda _epn _cN$T _dUIU _dYDXCP _dOPELS _dN$T _dEBLCP _dTEFOD _dU3W _dMERUC _dD6H _dOCLCQ
019			_a945611998
020			_a9780323354080 _q(electronic bk.)
020			_a0323354084 _q(electronic bk.)
020			_z9780323353236
035			_a(OCoLC)940961473 _z(OCoLC)945611998
050		4	_aRS201.N35
072		7	_aHEA _x012000 _2bisacsh
072		7	_aHEA _x020000 _2bisacsh
072		7	_aMED _x004000 _2bisacsh
072		7	_aMED _x101000 _2bisacsh
072		7	_aMED _x109000 _2bisacsh
072		7	_aMED _x029000 _2bisacsh
072		7	_aMED _x040000 _2bisacsh
072		7	_aMED _x092000 _2bisacsh
082	0	4	_a610.28 _223
245	0	0	_aAssessing nanoparticle risks to human health / _cedited by Gurumurthy Ramachandran.
250			_aSecond edition.
264		1	_aOxford, UK : _bWilliam Andrew is an imprint of Elsevier, _c2016.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aMicro and Nano Technologies
500			_aIncludes index.
588	0		_aOnline resource; title from PDF title page (ScienceDirect, viewed March 3, 2016).
505	0		_aFront Cover; Assessing Nanoparticle Risks to Human Health; Copyright Page; Contents; About the Editor; About the Contributors; Preface; 1 The Challenge of Nanomaterial Risk Assessment; 1.1 Introduction; 1.2 The Nature of the Nanomaterial Challenge; 1.3 The Problem with Definitions; 1.4 Principles-Based Problem Formulation for Engineered Nanomaterials; 1.4.1 Emergent Risk; 1.4.2 Plausibility; 1.4.3 Impact; 1.5 Applying the Three Principles to Engineered Nanomaterials; 1.5.1 Materials Demonstrating Abrupt Scale-Specific Changes in Biological or Environmental Behavior.
505	8		_a1.5.2 Materials Capable of Penetrating Normally Inaccessible Places1.5.3 Active Materials; 1.5.4 Materials Exhibiting Scalable Hazard That Is Not Captured by Conventional Risk Assessments; 1.6 Responsible Research and Innovation; 1.7 Looking Forward; References; 2 Assessing and Managing Exposures to Nanomaterials in the Workplace; 2.1 A General Strategy to Assess Workplace Exposures; 2.2 Uncertainties Introduced by Nanotechnology; 2.3 Exposure Routes; 2.3.1 Inhalation; 2.3.2 Dermal Exposure; 2.3.3 Ingestion; 2.4 Occupational Exposure Limits; 2.4.1 Permissible Exposure Limits from the OSHA.
505	8		_a2.4.2 Recommended Exposure Limits from the NIOSH2.4.3 Benchmark Limits; 2.5 Instruments Available to Assess Exposures; 2.5.1 Direct-Reading Instruments; Number concentration; Mass concentration; Surface area concentration; 2.5.2 Time-Integrated Measurements; Detailed characterization; Routine monitoring; 2.6 Specific "Best Practices" for Exposure Assessment Strategy in Nanotechnology; 2.6.1 Basic Characterization; Workplace and workforce; Characterizing nanomaterials; 2.6.2 Construction of Similar Exposure Groups Combined with Exposure Assessment; Concentration mapping.
505	8		_aJob-task-related measurementsBackground particles and incidental nanoparticles; 2.6.3 Interpretation of Exposure Assessment Results; Selecting occupational exposure limits; Defining the exposure profile; 2.6.4 Follow-Up and Control; References; 3 Hazard and Risk Assessment of Workplace Exposure to Engineered Nanoparticles: Methods, Issues, and Carbon Nanotub ... ; 3.1 Introduction; 3.1.1 Risk Assessment Paradigm; 3.1.2 Hazard Assessment; 3.1.3 Dose-Response Assessment; No observed or lowest observed adverse effect levels; Benchmark dose methods; Comparison of BMD and NOAEL/LOAEL estimates.
505	8		_a3.1.4 Interspecies and Temporal Extrapolation3.2 Case Study Example: Carbon Nanotubes; 3.2.1 Data Description; 3.2.2 Severity of Effects; 3.2.3 Quantitative Risk Assessment Procedures; Step 1. Evaluation of the exposure (or dose) and response data; Step 2. Estimation of a point of departure; Step 3. Estimation of rat lung dose; Step 4. Estimation of human-equivalent lung dose; Step 5. Risk characterization; 3.2.4 Considerations in the Derivation of OELs; 3.3 Discussion; 3.3.1 Comparison with Other Methods; 3.3.2 Research Needs; 3.3.3 Future Directions; References.
650		0	_aNanoparticles _xRisk assessment.
650		7	_aHEALTH & FITNESS _xHolism. _2bisacsh
650		7	_aHEALTH & FITNESS _xReference. _2bisacsh
650		7	_aMEDICAL _xAlternative Medicine. _2bisacsh
650		7	_aMEDICAL _xAtlases. _2bisacsh
650		7	_aMEDICAL _xEssays. _2bisacsh
650		7	_aMEDICAL _xFamily & General Practice. _2bisacsh
650		7	_aMEDICAL _xHolistic Medicine. _2bisacsh
650		7	_aMEDICAL _xOsteopathy. _2bisacsh
655		4	_aElectronic books.
700	1		_aRamachann, Gurumurthy, _eeditor.
776	0	8	_iPrint version: _aRamachandran, Gurumurthy. _tAssessing Nanoparticle Risks to Human Health. _d: Elsevier Science, �2016 _z9780323353236
830		0	_aMicro & nano technologies.
856	4	0	_3ScienceDirect _uhttp://www.sciencedirect.com/science/book/9780323353236
999			_c503836 _d503771